According to the USFDA guidance, a PD or clinical endpoint assessment may be employed if there are no quantifiable active constituents available for in vivo PK studies [30]. 3.2.4. In Silico Models: Multi-Omics and Systems Biology Approaches Reinforce Anticancer Foods Research As noted above, ...